Latest News and Press Releases
Want to stay updated on the latest news?
-
1Q 2018 revenue of $42.6 million1Q 2018 total tons sold of 723,000, the highest in Company history and an increase of 2% sequentially1Q 2018 net income of $1.0 million1Q 2018 Adjusted EBITDA of $5.9...
-
CALGARY, Alberta, May 08, 2018 (GLOBE NEWSWIRE) -- Bellatrix Exploration Ltd. (“Bellatrix”, "we", "us", "our" or the “Company”) (TSX:BXE) (NYSE:BXE) announces its financial and operating results for...
-
CALGARY, Alberta, May 07, 2018 (GLOBE NEWSWIRE) -- Bellatrix Exploration Ltd. (“Bellatrix” or the “Company”) (TSX:BXE) (NYSE:BXE) would like to remind shareholders they have until 3:00 pm (Calgary...
-
LINDON, Utah, May 03, 2018 (GLOBE NEWSWIRE) -- Profire Energy, Inc. (Nasdaq:PFIE), a technology company which creates, installs and services burner and chemical management solutions in the oil and...
-
ATM operating revenues down 6% for the quarter ATM operating revenues up 9% for the quarter excluding the impact of 7-Eleven Increases Outlook for 2018 HOUSTON, May 03, 2018 (GLOBE NEWSWIRE) -- ...
-
WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
-
1Q 2018 revenues of $218.1 million vs. $216.5 million in 4Q 2017 and $83.4 million in 1Q 20171Q 2018 net income of $53.9 million vs. $43.2 million in 4Q 2017 and net loss of $(6.8) million in 1Q...
-
THE WOODLANDS, Texas, May 01, 2018 (GLOBE NEWSWIRE) -- Smart Sand, Inc. (NASDAQ:SND) (the “Company”) announced today that it will release its first quarter 2018 financial results before the market...
-
First quarter sales of $67.3 million increased 24% sequentially and 73% from Q1 2017DynaEnergetics and NobelClad report sequential sales increases of 32% and 5%, respectivelyConsolidated gross margin...
-
WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...